نتایج جستجو برای: cladribine

تعداد نتایج: 689  

Journal: :European journal of neurology 2007
J E Martinez-Rodriguez D Cadavid L J Wolansky L Pliner S D Cook

Cladribine (2-chlorodeoxyadenosine) is an immunosuppressant drug previously evaluated in multiple sclerosis (MS) with variable results. We report six patients with aggressive relapsing MS who despite a poor response to other therapies had a favourable clinical evolution after cladribine. Four women and two men with a rapid increase in the number and severity of relapses leading to increasing di...

Journal: :Blood 2010
Darren S Sigal Heather J Miller Ethan D Schram Alan Saven

Before the contemporary development of rationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent. Its profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and a median duration of response of nearly a decade after only a single 7-day course, is well known and revolutionized the treatment of hairy cell leukemi...

2011
Per Soelberg Sorensen

ISSN 2041-6792 10.4155/CLI.10.32 © 2011 Future Science Ltd Treatment with cladribine leads to a preferential and sustained reduction in lymphocytes and monocytes, resulting in long-lasting depletion of CD4+ and CD8+ T cells. In the Phase III placebo-controlled trial in relapsing–remitting multiple sclerosis (the CLARITY study), oral cladribine at 96 weeks significantly reduced annual relapse ra...

Journal: :The New England journal of medicine 2010
Gavin Giovannoni Giancarlo Comi Stuart Cook Kottil Rammohan Peter Rieckmann Per Soelberg Sørensen Patrick Vermersch Peter Chang Anthony Hamlett Bruno Musch Steven J Greenberg

BACKGROUND Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis. METHODS We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or...

2017
Mohammad Hashemi Fatemeh Karami-Tehrani Saeed Ghavami

Cladribine, an analogue of deoxyadenosine, is highly toxic for both non-dividing and proliferating cells and has shown activity in the treatment of several malignancies. Therefore, the aim of the present study is to investigate the cytotoxicity effect of cladribine (2-CdA) on the breast cancer cell line, MCF7 (estrogen receptor positive, ER). MTT assay, annexin V-Fluorescein/PI and Hoechst 3325...

Journal: :Blood 2014
Joshua D Rosenberg Carol Burian Jill Waalen Alan Saven

Hairy cell leukemia (HCL) is a rare, indolent B-cell disorder in which single courses of cladribine induce high rates of complete responses. We report on 88 young HCL patients (≤40 years of age at diagnosis) treated with cladribine from the Scripps Clinic HCL Database, of whom 83 were evaluable for response. Seventy-three patients (88%) achieved an initial complete response and 10 (12%) a parti...

Journal: :international journal of hematology-oncology and stem cell research 0
mehrdad payandeh department of hematology and medical oncology, kermanshah university of medical sciences, kermanshah, iran. masoud sadeghi students research committee, kermanshah university of medical sciences, kermanshah, iran ; medical biology research center, kermanshah university of medical sciences, kermanshah, iran. edris sadeghi students research committee, kermanshah university of medical sciences, kermanshah, iran ; medical biology research center, kermanshah university of medical sciences, kermanshah, iran.

background: hairy cell leukemia (hcl) is a chronic b-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect. the study aims to evaluate a group of patients with hairy cell leukemia, hospitalized in the clinic of hematology and oncology, kermanshah, iran, on a pe...

Journal: :Blood 2003
Jorge Nieva Kelly Bethel Alan Saven

Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many patients (pts) ultimately relapse. Having relapsed after prior treatment with cladribine, 24 HCL pts (21 male, 3 female) with a median age of 53.5 years were treated with rituximab at 375 mg/m2 intravenously weekly for 4 weeks. Of the pts, 3 (13...

2016
Vivek Verma Smith Giri Vijaya Raj Bhatt Catalina Amador-Ortiz James O. Armitage

INTRODUCTION Concurrent hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) is rare; management is inadequately described in the literature. METHODS Retrospective chart review and clinical follow-up. RESULTS Five patients are described. The first patient developed synchronous HCL and CLL and was treated with rituximab for 13 months with HCL in remission and stable CLL. The seco...

Journal: :Acta haematologica 2007
France Laurencet Pierluigi Ballabeni Beatrice Rufener Urs Hess Thomas Cerny Martin Fey Jean-Marc Luthi Catherine Plancherel Gilbert B Zulian

A multicenter trial was performed to confirm the therapeutic efficacy and the toxicity profile of the combination of cladribine, cyclophosphamide and prednisone in low-grade non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Twenty-three adults with previously treated (61%) or untreated (39%) NHL International Working Formulation A or Binet B and C CLL were administered cladri...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید